期刊
JOURNAL OF CLINICAL ONCOLOGY
卷 32, 期 17, 页码 1830-U115出版社
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2013.53.1046
关键词
-
类别
资金
- Cancer Prevention and Research Institute of Texas, MD Anderson's Moon Shots Program [RP110609]
- Leukemia and Lymphoma Society Scholar Award in Clinical Research
Discovery of Bruton's tyrosine kinase (BTK) mutations as the cause for X-linked agammaglobulinemia was a milestone in understanding the genetic basis of primary immunodeficiencies. Since then, studies have highlighted the critical role of this enzyme in B-cell development and function, and particularly in B-cell receptor signaling. Because its deletion affects mostly B cells, BTK has become an attractive therapeutic target in autoimmune disorders and B-cell malignancies. Ibrutinib (PCI-32765) is the most advanced BTK inhibitor in clinical testing, with ongoing phase III clinical trials in patients with chronic lymphocytic leukemia and mantle-cell lymphoma. In this article, we discuss key discoveries related to BTK and clinically relevant aspects of BTK inhibitors, and we provide an outlook into clinical development and open questions regarding BTK inhibitor therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据